News
September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns FDA
The warning letter was one of about 100 sent to crack down on deceptive direct-to-consumer drug advertisements.
[...]September 8, 2025: FDA launches an import alert listing safe GLP-1 manufacturers
The “green list” will help protect patients from unreliable, illegally compounded GLP-1s and simplify screening for border security.
[...]PSM leads letter in support of an FDA mandate to destroy high-risk imports
PSM led a coalition of organizations urging leaders of the Senate HELP and House Energy and Commerce committees to help strengthen the FDA’s ability to protect Americans from unsafe and counterfeit medicines and medical products.
[...]10 years of fentanyl pills
A decade ago no one had heard of deadly counterfeit prescription pills. Victims’ families bravely spoke up, lobbied, and rallied for change.
[...]September 2, 2025: U.S. compounding restrictions have stemmed a flood of compounded semaglutide and tirzepatide
Chinese companies that supplied U.S. compounders have turned to making generic semaglutide for markets where Novo Nordisk’s main patent is expiring in 2026.
[...]This week: New press draws attention to the dangers of poorly regulated medspas
Elle published an exposé about bad actors and loose regulation in the medical spa industry.
[...]August 18, 2025: PSM, ADAP ask New York’s Board of Pharmacy to act in alleged fake medicine case
On August 7, the Partnership for Safe Medicines and ADAP Advocacy Association filed a complaint asking the New York State Board of Pharmacy to take regulatory action against a pharmacy that allegedly sold counterfeit HIV medicine to a Queens, New York patient.
[...]Public health groups raise alarm about fake HIV medicines in New York
PSM and ADAP Advocacy Association filed an official complaint with the State of New York regarding allegations that City Plus Care Pharmacy Inc. dispensed counterfeit HIV medication to a patient in Queens, New York.
[...]August 11, 2025: The FDA voices concern about sites that supply compounding ingredients
Statistics in the agency’s Report on the State of Pharmaceutical Quality show that active pharmaceutical ingredient (API) sites that solely supply compounding pharmacies are disproportionately high risk.
[...]PSM signs letter of support for changes to Mississippi’s compounding pharmacy guidelines
The proposed updates aim to help address safety concerns created by pharmacies reselling compounded sterile drugs purchased from outsourcing facilities.
[...]